Search Results - "Thijs, Judith"

Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis by Thijs, Judith L., MD, Strickland, Ian, PhD, Bruijnzeel-Koomen, Carla A.F.M., MD, PhD, Nierkens, Stefan, PhD, Giovannone, Barbara, PhD, Csomor, Eszter, PhD, Sellman, Bret R., PhD, Mustelin, Tomas, MD, PhD, Sleeman, Matthew A., PhD, de Bruin-Weller, Marjolein S., MD, PhD, Herath, Athula, PhD, Drylewicz, Julia, PhD, May, Richard D., PhD, Hijnen, DirkJan, MD, PhD

“…Background Atopic dermatitis (AD) is a complex, chronic, inflammatory skin disease with a diverse clinical presentation. However, it is unclear whether this…”
Get full text

Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry by Ariëns, Lieneke F. M., Schaft, Jorien, Bakker, Daphne S., Balak, Deepak, Romeijn, Margreet L. E., Kouwenhoven, Tessa, Kamsteeg, Marijke, Giovannone, Barbara, Drylewicz, Julia, Amerongen, Cynthia Catalina Aurora, Delemarre, Evelien M., Knol, Edward F., Wijk, Femke, Nierkens, Stefan, Thijs, Judith L., Schuttelaar, Marie L. A., Bruin‐Weller, Marjolein S.

“…Introduction Dupilumab has recently been approved for the treatment of moderate to severe atopic dermatitis (AD) in adults. Daily practice data on dupilumab…”
Get full text

Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers by Bakker, Daphne S., Nierkens, Stefan, Knol, Edward F., Giovannone, Barbara, Delemarre, Eveline M., van der Schaft, Jorien, van Wijk, Femke, de Bruin-Weller, Marjolein S., Drylewicz, Julia, Thijs, Judith L.

“…Atopic dermatitis (AD) is a highly heterogeneous disease, both clinically and biologically, whereas patients are still being treated according to a…”
Get full text

Unraveling heterogeneity in pediatric atopic dermatitis: Identification of serum biomarker based patient clusters by Bakker, Daphne S., de Graaf, Marlies, Nierkens, Stefan, Delemarre, Eveline M., Knol, Edward, van Wijk, Femke, de Bruin-Weller, Marjolein S., Drylewicz, Julia, Thijs, Judith L.

“…Increasing evidence shows that pediatric atopic dermatitis (AD) differs from adult AD on a biologic level. Broad biomarker profiling across a wide range of…”
Get full text

Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis by Bakker, Daphne S., van der Wal, Maria M., Heeb, Lukas E.M., Giovannone, Barbara, Asamoah, Mindy, Delemarre, Eveline M., Drylewicz, Julia, Nierkens, Stefan, Boyman, Onur, de Bruin-Weller, Marjolein S., Thijs, Judith L., van Wijk, Femke

“…Dupilumab, a mAb targeting IL-4 receptor alpha (IL-4Rα), markedly improves disease severity in patients with atopic dermatitis. However, the effect of IL-4Rα…”
Get full text

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry by Ariëns, Lieneke F.M., van der Schaft, Jorien, Spekhorst, Lotte S., Bakker, Daphne S., Romeijn, Geertruida L.E., Kouwenhoven, Tessa A., Kamsteeg, Marijke, Voorberg, Angelique N., Oosting, Albert J., de Ridder, Ilona, Sloeserwij, Annemieke, Haeck, Inge, Thijs, Judith L., Schuttelaar, Marie L.A., de Bruin-Weller, Marjolein S.

“…Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited. To study 52-week effectiveness and safety of…”
Get full text

ZFP36 Family Members Regulate the Proinflammatory Features of Psoriatic Dermal Fibroblasts by Angiolilli, Chiara, Leijten, Emmerik F.A., Bekker, Cornelis P.J., Eeftink, Ella, Giovannone, Barbara, Nordkamp, Michel Olde, van der Wal, Marlot, Thijs, Judith L., Vastert, Sebastiaan J., van Wijk, Femke, Radstake, Timothy R.D.J., van Loosdregt, Jorg

“…Dermal fibroblasts are strategically positioned underneath the basal epidermis layer to support keratinocyte proliferation and extracellular matrix production…”
Get full text

Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients by Achten, Roselie E., Bakker, Daphne S., Luijk, Chantal M., Wal, Marlot, Graaf, Marlies, Wijk, Femke, Zuithoff, Nicolaas P.A., Rijst, Lisa P., Boesjes, Celeste M., Thijs, Judith L., Boer, Joke H., Bruin‐Weller, Marjolein S.

Get full text

Serum biomarker profiles suggest that atopic dermatitis is a systemic disease by Thijs, Judith L., Strickland, Ian, Bruijnzeel-Koomen, Carla A.F.M., Nierkens, Stefan, Giovannone, Barbara, Knol, Edward F., Csomor, Eszter, Sellman, Bret R., Mustelin, Tomas, Sleeman, Matthew A., de Bruin-Weller, Marjolein S., Herath, Athula, Drylewicz, Julia, May, Richard D., Hijnen, DirkJan

“…The component loadings showed that principal component 1 (explaining 23% of variability) is primarily driven by IL-5, IL-1β, IL-7, IL-1R1, and IL-15; principal…”
Get full text

Multiplex platform technology and bioinformatics are essential for development of biomarkers in atopic dermatitis by Thijs, Judith L., MD, Herath, Athula, PhD, de Bruin-Weller, Marjolein S., MD, PhD, Hijnen, DirkJan, MD, PhD

“…[...]we recently conducted a pilot study in which we demonstrated that a multivariate signature, consisting of serum TARC, PARC/CCL18, IL-22, and sIL-2R…”
Get full text

Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry by Spekhorst, Lotte S., Ariëns, Lieneke F.M., Schaft, Jorien, Bakker, Daphne S, Kamsteeg, Marijke, Oosting, Albert J., Ridder, Ilona, Sloeserwij, Annemiek, Romeijn, Geertruida L.E., Graaf, Marlies, Haeck, Inge, Thijs, Judith L., Schuttelaar, Marie L.A., de Bruin‐Weller, Marjolein S.

Get full text

EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers by Bakker, Daphne S., Ariens, Lieneke F. M., Giovannone, Barbara, Hijnen, DirkJan, Delemarre, Eveline M., Knol, Edward, Nierkens, Stefan, Bruin‐Weller, Marjolein S., Thijs, Judith L., Drylewicz, Julia

Get full text

Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis by Achten, Roselie E, Van Luijk, Chantal, Van der Rijst, Lisa, Bakker, Daphne, Spekhorst, Lotte, Zuithoff, Nicolaas, Schuttelaar, Marie, Romeijn, Geertruida, Voorberg, Angelique, Kamsteeg, Marijke, Haeck, Inge, De Graaf, Marlies, Thijs, Judith, De Boer, Joke, De Bruin-Weller, Marjolein

“…This study identified risk factors for the development of dupilumab-associated ocular surface disease in patients with moderate-to-severe atopic dermatitis in…”
Get full text

Conjunctival inflammation in dupilumab‐treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study by Bakker, Daphne S., ter Linde, José J. M., Amini, Mojtaba M., Ariëns, Lieneke F. M., van Luijk, Chantal M., de Bruin‐Weller, Marjolein S., Thijs, Judith L., Vercoulen, Yvonne, van Wijk, Femke

Get full text

Current and Future Biomarkers in Atopic Dermatitis by Thijs, Judith L., MD, de Bruin-Weller, Marjolein S., MD, PhD, Hijnen, DirkJan, MD, PhD

“…Atopic dermatitis (AD) is a heterogeneous disease and many attempts have been made to define subsets of patients based on clinical characteristics. However,…”
Get full text

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry by Ariëns, Lieneke F M, Bakker, Daphne S, Spekhorst, Lotte S, Van der Schaft, Jorien, Thijs, Judith L, Haeck, Inge, Flinterman, Annebeth E, Kamsteeg, Marijke, Schuttelaar, Marie L A, De Bruin-Weller, Marjolein S

“…Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of…”
Get full text

EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients by Thijs, Judith L., Drylewicz, Julia, Fiechter, Renée, Strickland, Ian, Sleeman, Matthew A., Herath, Athula, May, Richard D., Bruijnzeel-Koomen, Catharina A.F.M., Knol, Edward F., Giovannone, Barbara, de Bruin-Weller, Marjolein S., Nierkens, Stefan, Hijnen, Dirk Jan

“…Combining levels of biomarkers in an algorithm provides a single, easy-to-interpret value. Because the algorithm was developed to predict EASI scores, we named…”
Get full text

Towards personalized treatment in atopic dermatitis by van der Schaft, Jorien, Thijs, Judith L, Garritsen, Floor M, Balak, D, de Bruin-Weller, Marjolein S

“…For many years, oral immunosuppressive drugs such as cyclosporine A, azathioprine, mycophenolic acid, and methotrexate were the only treatment options, in…”
Get more information

Dupilumab after the 2017 approval for the treatment of atopic dermatitis: whatʼs new and whatʼs next? by van der Schaft, Jorien, Thijs, Judith L, de Bruin-Weller, Marjolein S, Balak, Deepak M.W

“…PURPOSE OF REVIEWThe IL-4/13 antagonist dupilumab was approved in 2017 as the first biologic for atopic dermatitis. Here, we comprehensively review compelling…”
Get full text

Biomarkers detected in dried blood spots from atopic dermatitis patients strongly correlate with disease severity by Thijs, Judith L., Fiechter, Renée, Giovannone, Barbara, de Bruin‐Weller, Marjolein S., Knol, Edward F., Bruijnzeel‐Koomen, Carla A. F. M., Drylewicz, Julia, Nierkens, Stefan, Hijnen, DirkJan

Get full text